ESPRのチャート
ESPRの企業情報
| symbol | ESPR |
|---|---|
| 会社名 | Esperion Therapeutics Inc (New) （エスペリオン・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 エスペリオン・セラピューティクス（Esperion Therapeutics Inc.）は脂質管理会社である。同社は低密度リポタンパク質コレステロール（LDL-C）上昇患者の治療用の1日に1回の経口療法の開発・商業化に焦点を当てた後期の製薬会社である。標的とする作用機序を有するベムドエイド酸は、経口投与が可能な1日1回のアデノシン三リン酸（ATP） - クエン酸リアーゼ（ACL）阻害剤であり、コレステロール生合成を低下させ、LDL- LDL受容体を調節するが、筋肉関連の副作用の可能性が低下する。単独療法としてのベムドエ酸に加えて、同社は、認可された非スタチン系の経口LDL-C降下療法であるエゼチミブと一定用量の組み合わせで、ベムドエ酸を開発中である。 エスペリオン・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。高コレステロ―ル血症及び、その他の心臓代謝リスクマ―カ―を有する患者の治療のため、低比重リポタンパクコレステロ―ル濃度を低下させる治療法の開発、商業化に従事。経口治療薬と小分子治療薬を開発する。本社はミシガン州。 Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world. |
| 本社所在地 | 3891 Ranchero Drive Suite 150 Ann Arbor MI 48108 USA |
| 代表者氏名 | Timothy M. Mayleben ティモシー・M・メレイベン |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 734-887-3903 |
| 設立年月日 | 39448 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | － |
| url | www.esperion.com |
| nasdaq_url | https://www.nasdaq.com/symbol/espr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -177.55900 |
| 終値（lastsale） | 44.48 |
| 時価総額（marketcap） | 1192227464 |
| 時価総額 | 時価総額（百万ドル） 1219.299 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 139.278 |
| 当期純利益 | 当期純利益（百万ドル） -174.97000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Esperion Therapeutics Inc revenues was not reported. Net loss increased 10% to $91.9M. Higher net loss reflects Research and development increase of 9% to $80.5M (expense) General and administrative increase of 24% to $12.9M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$3.72 to -$3.44. |
ESPRのテクニカル分析
ESPRのニュース
It would be worthwhile to take a closer look at Esperion Therapeutics Inc. (ESPR) 2022/12/27 16:54:00 US Post News
The share price of Esperion Therapeutics Inc. (NASDAQ:ESPR) fell to $6.07 per share on Friday from $6.36. While Esperion Therapeutics Inc. has underperformed by -4.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ESPR rose by 12.83%, with highs and lows ranging from $8.87 to $3.28, […]
Esperion Therapeutics Inc. (ESPR) Has Strong Growth Prospects Through 2022 2022/12/14 15:00:00 Marketing Sentinel
Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 0.23 and has seen 2.43 million shares traded in the last trading session. The company, currently valued at $501.03M, closed the last trade at $5.60 per share which meant it gained $0.23 on the day or 4.28% during that session. The ESPR stock price is -58.39% … Esperion Therapeutics Inc. (ESPR) Has Strong Growth Prospects Through 2022 Read More »
Observations on the Esperion Therapeutics Inc. (NASDAQ:ESPR) Growth Curve 2022/12/12 18:00:00 US Post News
Esperion Therapeutics Inc. (ESPR)’s stock has witnessed a price declined of -0.29% from the previous close with its current price standing at $5.07. Its current price is -42.78% under its 52-week high of $8.87 and 54.73% more than its 52-week low of $3.28. Based on the past 30-day period, the stock price is -42.90% below […]
Following Its 52-Week Low, Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Share Price Rose 35.56% And Its YTD Numbers Rise 1.80% 2022/12/10 13:30:00 Marketing Sentinel
During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 7.06 million, with the beta value of the company hitting 0.21. At the end of the trading day, the stock’s price was $5.09, reflecting an intraday loss of -17.64% or -$1.09. The 52-week high for the ESPR share is $8.87, that puts it down … Following Its 52-Week Low, Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Share Price Rose 35.56% And Its YTD Numbers Rise 1.80% Read More »
2 Biotech Stocks Options Traders Love Today - Schaeffer''s Investment Research 2022/12/07 17:16:01 Schaeffers Investment Research
Prometheus Biosciences (RXDX) and Esperion Therapeutics (ESPR) are both making waves following drug updates
Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) 2021/10/26 00:22:28 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) appeared first on Stocks Equity .
Analysts Expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post -$2.86 EPS 2021/10/25 23:26:41 Dakota Financial News
Wall Street brokerages forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report ($2.86) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics earnings. The lowest EPS estimate is ($3.05) and the highest is ($2.63). Esperion Therapeutics reported earnings of ($3.07) per share in the same quarter []
Zacks: Analysts Anticipate Esperion Therapeutics, Inc. (NASDAQ:ESPR) Will Announce Quarterly Sales of $12.31 Million 2021/10/25 23:26:41 Transcript Daily
Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report sales of $12.31 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics earnings, with the highest sales estimate coming in at $13.00 million and the lowest estimate coming in at $11.23 million. Esperion Therapeutics posted sales []
SG Americas Securities LLC Cuts Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) 2021/10/23 09:26:41 Dakota Financial News
SG Americas Securities LLC lessened its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 14.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,844 shares of the biopharmaceutical companys stock after selling 2,422 shares during the period. SG Americas []
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Credit Suisse Group to Neutral 2021/10/22 06:20:41 Dakota Financial News
Credit Suisse Group lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from an outperform rating to a neutral rating in a report released on Monday, PriceTargets.com reports. The firm currently has $11.00 price target on the biopharmaceutical companys stock, down from their previous price target of $28.00. Several other equities analysts also recently issued reports on the []
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street 2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
Esperion Therapeutics Inc. Shares Approach 52-Week Low - Market Mover 2021/07/18 14:15:23 Kwhen Finance
Esperion Therapeutics Inc. (ESPR) shares closed today at 0.5% above its 52 week low of $17.36, giving the company a market cap of $491M. The stock is currently down 32.9% year-to-date, down 63.8% over the past 12 months, and up 56.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 49.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 194.2% The company's stock price performance over the past 12 months lags the peer average by -7546.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs 2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
Comprehensive Report on Heterozygous Familial Hypercholesterolemia Drug Market by 2027 | Daewoong Co Ltd, Esperion Therapeutics Inc, Gemphire Therapeutics Inc 2021/07/15 10:46:32 Tramways Monthly
Heterozygous Familial Hypercholesterolemia Drug Market research report is the new statistical data source added by A2Z Market Research. It uses several approaches for analyzing the data of target market such as primary and secondary research methodologies. It includes investigations based on historical records, current statistics, and futuristic developments. The report gives a thorough overview of the []